Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 9/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | RECQL | P46063 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123049 | 0.90 | IMPDH2 (0.46) | IMPDH2ABCG2MEN1KMT2ARAB9A | |
| SCHEMBL3131343 | 0.85 | MAPT (0.53) | IMPDH2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3131353 | 0.85 | MAPT (0.53) | IMPDH2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3134288 | 0.81 | MAPT (0.52) | IMPDH2ABCG2MEN1KMT2ARAB9A | |
| SCHEMBL3138018 | 0.80 | IMPDH2 (0.46) | IMPDH2ABCG2MEN1KMT2ARAB9A | |
| SCHEMBL3123041 | 0.76 | MAPT (0.56) | IMPDH2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL3123056 | 0.76 | MAPT (0.56) | IMPDH2MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL13763144 | 0.70 | GPR55 (0.38) | IMPDH2MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL3131280 | 0.66 | MAPT (0.58) | IMPDH2MEN1KMT2ARAB9AMAPT | |
| SCHEMBL13757053 | 0.66 | KMT2A (0.53) | IMPDH2ABCG2MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2021333-B1 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S (IT) | 2010-07-14 | — | — | EP | claimed |
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2009-08-13 | — | — | US | claimed |
| EP-2021333-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS - Ethical Oncology Science S.p.A. (IT) | 2009-02-11 | — | — | EP | claimed |
| WO-2007135565-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2007-11-29 | — | — | WO | claimed |
| EP-2021333-B1 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS ETHICAL ONCOLOGY SCIENCE S (IT) | 2010-07-14 | — | — | EP | disclosed |
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2009-08-13 | — | — | US | disclosed |
| EP-2021333-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS - Ethical Oncology Science S.p.A. (IT) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007135565-A2 | ANTI-PROLIFERATIVE COMPOUNDS DERIVING FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | EOS (ETHICAL ONCOLOGY SCIENCE) S.P.A. (IT) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203685-A1 | ANTI-PROLIFERATIVE COMPOUNDS FROM A 3-ARYL-COUMARINE OR 3-ARYL-QUINOLIN-2-ONE AND USES THEREOF | MKI67, CCNA1, CCNI | IMPDH2 3546/4885ABCG2 381/4885MEN1 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.